S3-Leitlinie Prostatakarzinom - AWMF

9. Literatur
135. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term followup
of a large, active surveillance cohort with localized prostate cancer. Journal of clinical
oncology : official journal of the American Society of Clinical Oncology 2010;28(1):126-31.
http://www.ncbi.nlm.nih.gov/pubmed/19917860
136. Shappley WV, III, Kenfield SA, Kasperzyk JL, Qiu W, Stampfer MJ, Sanda MG, Chan JM.
Prospective study of determinants and outcomes of deferred treatment or watchful waiting
among men with prostate cancer in a nationwide cohort. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(30):4980-5.
http://www.ncbi.nlm.nih.gov/pubmed/19720918
137. Sugimoto M, Shiraishi T, Tsunemori H, Demura T, Saito Y, Kamoto T, Kakehi Y. Pathological
findings at radical prostatectomy in Japanese prospective active surveillance cohort. Jpn J
Clin Oncol 2010;40(10):973-9. http://www.ncbi.nlm.nih.gov/pubmed/20534686
138. Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J. PSA doubling time predicts
the outcome after active surveillance in screening-detected prostate cancer: results from
the European randomized study of screening for prostate cancer, Sweden section. Int J
Cancer 2007;120(1):170-4. http://www.ncbi.nlm.nih.gov/pubmed/17013897
139. Klotz L. Active surveillance for prostate cancer: for whom? Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2005;23(32):8165-9.
http://www.ncbi.nlm.nih.gov/pubmed/16278468
140. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schroder F.
Insignificant prostate cancer and active surveillance: from definition to clinical implications.
Eur Urol 2009;55(6):1321-30. http://www.ncbi.nlm.nih.gov/pubmed/19286302
141. Parker C. Active surveillance: towards a new paradigm in the management of early prostate
cancer. Lancet Oncol 2004;5(2):101-6. http://www.ncbi.nlm.nih.gov/pubmed/14761814
142. Parker C. The Scandinavian Prostate Cancer Group Study: the case for conservative
management. BJU Int 2005;96(7):952-3. http://www.ncbi.nlm.nih.gov/pubmed/16225505
143. Aus G, Robinson D, Rosell J, Sandblom G, Varenhorst E. Survival in prostate carcinoma--
outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of
follow-up: results from three countries in the population-based National Prostate Cancer
Registry of Sweden. Cancer 2005;103(5):943-51.
http://www.ncbi.nlm.nih.gov/pubmed/15651057
144. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically
localised prostate cancer. Lancet 1997;349(9056):906-10.
http://www.ncbi.nlm.nih.gov/pubmed/9093251
145. McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression?:
Prostate specific antigen doubling times and clinical behavior in patients with early
untreated prostate carcinoma. Cancer 1998;82(2):342-8.
http://www.ncbi.nlm.nih.gov/pubmed/9445192
146. Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, Kattan MW, Monfardini S,
Moul JW, Naeim A, Van PH, Saad F, Sternberg CN. Management of prostate cancer in older
men: recommendations of a working group of the International Society of Geriatric
Oncology. BJU Int 2010;106(4):462-9. http://www.ncbi.nlm.nih.gov/pubmed/20346033
147. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, Nordling S, Haggman M,
Andersson SO, Bratell S, Spangberg A, Palmgren J, Adami HO, Johansson JE. Radical
prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian
prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100(16):1144-54.
http://www.ncbi.nlm.nih.gov/pubmed/18695132
© Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 2.0, 1. Aktualisierung 2011